Ivan Bergstein
Chief Executive Officer at STEMLINE THERAPEUTICS, INC.
Profile
Ivan Bergstein is the founder of Stemline Therapeutics, Inc., which was founded in 2003.
He is currently the President & Chief Executive Officer of Stemline Therapeutics, Inc. Dr. Bergstein is also the Chairman of Lirum Therapeutics, Inc., where he started in 2021.
In his former positions, Dr. Bergstein worked as a Medical Director at Keryx Biopharmaceuticals, Inc. and ACCESS Oncology, Inc., and as a Senior Biopharmaceuticals Analyst at Nitron Advisors.
Dr. Bergstein received his undergraduate degree from the University of Pennsylvania and his doctorate from the Icahn School of Medicine at Mount Sinai.
Ivan Bergstein active positions
| Companies | Position | Start |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Chief Executive Officer | - |
Lirum Therapeutics, Inc.
 Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Chairman | 31/10/2021 |
Former positions of Ivan Bergstein
| Companies | Position | End |
|---|---|---|
Nitron Advisors
 Nitron Advisors Investment ManagersFinance Nitron Advisors operates an investment research company. The private company is based in Saratoga, CA. | Corporate Officer/Principal | - |
| KERYX BIOPHARMACEUTICALS | Chief Tech/Sci/R&D Officer | - |
ACCESS Oncology, Inc.
 ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Part of Akebia Therapeutics, Inc., ACCESS Oncology, Inc. is a private company that develops pharmaceutical drugs. The company is based in New York, NY. The company was founded by Michael Sean Weiss. ACCESS Oncology was acquired by Keryx Biopharmaceuticals, Inc., part of Akebia Therapeutics, Inc. from December 13, 2018 on February 06, 2004 for $36.44 million. | Chief Tech/Sci/R&D Officer | - |
Training of Ivan Bergstein
| University of Pennsylvania | Undergraduate Degree |
| Icahn School of Medicine at Mount Sinai | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
 | Health Technology |
| Private companies | 4 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
ACCESS Oncology, Inc.
ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Part of Akebia Therapeutics, Inc., ACCESS Oncology, Inc. is a private company that develops pharmaceutical drugs. The company is based in New York, NY. The company was founded by Michael Sean Weiss. ACCESS Oncology was acquired by Keryx Biopharmaceuticals, Inc., part of Akebia Therapeutics, Inc. from December 13, 2018 on February 06, 2004 for $36.44 million. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Nitron Advisors
Nitron Advisors Investment ManagersFinance Nitron Advisors operates an investment research company. The private company is based in Saratoga, CA. | Finance |
- Stock Market
- Insiders
- Ivan Bergstein
